Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk

Dow Jones04-15

1401 GMT - Bayer's consumer-healthcare unit remains an attractive asset and its size and geographic footprint make it a good acquisition target should the German company decide to put it up for sale at some point, Barclays analysts say in a research note. The agricultural-and-pharmaceuticals group last month ruled out changes to its structure for now, but left the door open to consider its options in the future. Reckitt Benckiser, Procter & Gamble and Nestle seem to have the least overlap with Bayer's consumer-healthcare portfolio and would face less competition issues in a potential pursuit, Barclays says. Haleon and Kenvue's big overlaps with Bayer's consumer-healthcare sales would make them the most disadvantaged buyers from a regulatory perspective, Barclays says. Bayer shares fall 0.9%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

April 15, 2024 10:01 ET (14:01 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2427009497?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-15 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2427009497","market":"sg","top_or_hot":-1,"title":"Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1401 GMT - Bayer's consumer-healthcare unit remains an attractive asset and its size and geographic footprint make it a good acquisition target should the German company decide to put it up for sale at some point, Barclays analysts say in a research note. The agricultural-and-pharmaceuticals group last month ruled out changes to its structure for now, but left the door open to consider its options in the future. Reckitt Benckiser, Procter &amp; Gamble and Nestle seem to have the least overlap with Bayer's consumer-healthcare portfolio and would face less competition issues in a potential pursuit, Barclays says. <a href=\"https://laohu8.com/S/HLN\">Haleon</a> and Kenvue's big overlaps with Bayer's consumer-healthcare sales would make them the most disadvantaged buyers from a regulatory perspective, Barclays says. Bayer shares fall 0.9%. (adria.calatayud@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 15, 2024 10:01 ET (14:01 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-15 22:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1401 GMT - Bayer's consumer-healthcare unit remains an attractive asset and its size and geographic footprint make it a good acquisition target should the German company decide to put it up for sale ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HCSG","symbol_name":"医疗保健服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2427009497","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2427009497","pubTimestamp":1713189660,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1401 GMT - Bayer's consumer-healthcare unit remains an attractive asset and its size and geographic footprint make it a good acquisition target should the German company decide to put it up for sale at some point, Barclays analysts say in a research note. The agricultural-and-pharmaceuticals group last month ruled out changes to its structure for now, but left the door open to consider its options in the future. Reckitt Benckiser, Procter & Gamble and Nestle seem to have the least overlap with Bayer's consumer-healthcare portfolio and would face less competition issues in a potential pursuit, Barclays says. Haleon and Kenvue's big overlaps with Bayer's consumer-healthcare sales would make them the most disadvantaged buyers from a regulatory perspective, Barclays says. Bayer shares fall 0.9%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HCSG":"医疗保健服务","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4137":"综合支持服务","LU0823411888.USD":"法巴消费创新基金 Cap","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","KVUE":"Kenvue Inc","BK4212":"包装食品与肉类","BK4532":"文艺复兴科技持仓","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","BK4018":"居家用品","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4585":"ETF&股票定投概念","PG":"宝洁","03165":"华夏欧优股对冲","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","RBGLY":"Reckitt Benckiser Group Plc.","BK4114":"综合货品商店","NSRGY":"雀巢","TGT":"塔吉特","BK4588":"碎股","BAYRY":"Bayer A.G.","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","BK4155":"大卖场与超市","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK4504":"桥水持仓","BK4183":"个人用品"},"translate_title":"拜耳的消费者医疗保健部门仍然是有吸引力的收购目标——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGT":1,"HCSG":1,"BAYRY":0.9,"RBGLY":0.9,"PG":0.9,"NSRGY":0.9,"KVUE":0.9,"03165":0.6},"content_text":"1401 GMT - Bayer's consumer-healthcare unit remains an attractive asset and its size and geographic footprint make it a good acquisition target should the German company decide to put it up for sale at some point, Barclays analysts say in a research note. The agricultural-and-pharmaceuticals group last month ruled out changes to its structure for now, but left the door open to consider its options in the future. Reckitt Benckiser, Procter & Gamble and Nestle seem to have the least overlap with Bayer's consumer-healthcare portfolio and would face less competition issues in a potential pursuit, Barclays says. Haleon and Kenvue's big overlaps with Bayer's consumer-healthcare sales would make them the most disadvantaged buyers from a regulatory perspective, Barclays says. Bayer shares fall 0.9%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 15, 2024 10:01 ET (14:01 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2427009497"}